Hiperamonyeminin Nadir Bir Nedeni: Valproik Asit Zehirlenmesi

Giriş: Valproik asit (VA) epilepsi ve bipolar duygu durum bozukluğu tedavisinde ayrıca migren profilaksisinde yaygın olarak kullanılan geniş spektrumlu bir antiepileptiktir. Yüksek doz alımlar, letarjiden komaya kadar değişen merkezi sinir sistemi (MSS) depresyonuna, solunum yetmezliğine, böbrek yetmezliğine, akut pankreatite, hepatotoksisiteye ve kemik iliği depresyonuna neden olabilmektedir. Olgu Sunumu: Biz bu yazıda akut masif doz VA’ in neden olduğu hiperamonyemik ensefalopatili olgunun L-karnitin ile tedavisini son literatürler ışığında incelemeye çalıştık. Sonuç: Acil servislerde (AS) nadir görülen bir zehirlenme olan VA zehirlenmelerinde; ciddi zehirlenme bulguları ile beraber hiperamonyemi varsa L-karnitin tedavisi akılda tutulması gereken bir tedavi yaklaşımıdır.

A Rare Reason of Hyperammonemia: Valproic Acid Poisoning

Introduction: Valproic acid (VA) is a broad-spectrum antiepileptic drug that is widely used in the treatment of epilepsy and bipolar affective disorder and also in the prophylaxis of migraine. High doses can cause central nervous system depression ranging from lethargy to coma, respiratory failure, renal failure, acute pancreatitis, hepatotoxicity, and bone marrow depression.Case Report: In this paper, we attempted to examine a case of acute encephalopathy with hyperammonemia caused by high doses of VA and treated with L-carnitine based on the recent literature.Conclusion: In patients with hyperammonemia associated with the severe toxicity symptoms of poisoning, L-carnitine administration is a treatment approach to keep in mind based on the rare types of poisoning observed at emergency services

___

  • Temrel TA, İzdeş S, Celik GK, Altıntaş D, Kavaklı HŞ, Ahmedali A. Suc- cessful treatment of valproic acid ıntoxication with hemodialysis and l-carnitine. JAEMCR 2013; 4: 10-2. [CrossRef]
  • Satar S, Bozdemir MN. Antiepiletik ilaçlarla zehirlenmeler. Acilde Klinik Toksikoloji. Adana: Nobel Tıp Kitabevi, 1th ed. 2009 p. 331-37.
  • Sztajnkrycer MD. Valproic acid toxicity: Overview and management. J Toxicol Clin Toxicol 2002; 40: 789-01. [CrossRef]
  • Al Aly Z, Yalamanchili P, Gonzalez E. Extracorporeal management of valproic acid toxicity: A case report and review of the literature. Semin Dial 2005; 18: 62-6.
  • Temel V, Arikan M, Temel G. High-flux hemodialysis and levocarnitine in the treatment of severe valproic acid ıntoxication. Hindawi Publishing Corporation Case Reports in Emergency Medicine Vol. 2013, Article ID 526469, 3 pages, 2013.
  • Eryılmaz G, Gül IG, Ünsalver BÖ, Salçini C, Sağlam E. Valproik asit kullanı- mına bağlı gelişen hiperamonyemik ensefalopati: Vaka sunumu. Jour- nal of Mood Disorders 2014; 4: 182-5.
  • Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdo- se: A systematic review of published cases. Ann Pharmacother 2010; 44: 1287-93. [CrossRef]
  • Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz KD, Zilker T. Acute valproate poisoning: Pharmacokinetics, alteration in fatty acid meta- bolism, and changes during therapy. J Clin Psychopharmacol 2005; 25: 376-80. [CrossRef]
  • Spiller HA, Krenzelok EP, Klein-Schwartz W, Winter ML, Weber JA, Sollee DR, et al. Multicenter case series of valproic acid ingestion: Serum con- centrations and toxicity. J Toxicol Clin Toxicol 2000; 38: 755-60. [CrossRef]
  • Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, et al. Acetyl-L-carnitine improves cognitive functions in seve- re hepatic encephalopathy: A randomized and controlled clinical trial. Metab Brain Dis 2011; 26: 281-9.[CrossRef]